Medical Director, Cardio Metabolic Endocrine Franchise Cleveland Heart Lab / Quest Diagnostics
Dr. Marc Penn is a practicing cardiologist, Director of Research and Program Director for the Cardiovascular Medicine Fellowship at Summa Health Heart and Vascular Institute (Akron, OH). He is a Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University (Rootstown, OH). He is the Chief Medical Officer of Diasome, Inc. (Cleveland, OH). From 2000-11 Dr. Penn was a cardiologist at the Cleveland Clinic where he served as the Director of the Coronary Intensive Care Unit, Director of the Experimental Animal Laboratory, Director of the Bakken Heart-Brain Institute, and the Founding Director of the Center for Cardiovascular Cell Therapy.
Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University completing a Ph.D. in Biomedical Engineering in 1989 and Doctor of Medicine in 1994. He completed his Internal Medicine training at University Hospitals of Cleveland (1994-97) and his Cardiovascular Medicine Fellowship at Cleveland Clinic (1997-2000). He is board certified in Internal Medicine and Cardiovascular Medicine. During his training he received numerous awards including the 2000 Joseph Cash Memorial Prize for Clinical Outcomes Research and the 1999 Irvine H. Page Young Investigator award for Atherosclerosis Research presented by the National American Heart Association. He has adjunct appointments at Case Western Reserve University in Biomedical Engineering and in the Bioengineering Center at Cleveland State University.
Dr. Penn’s research has led to several discoveries in the field of cardiovascular medicine including in diagnostics, strategies to optimize gene and stem cell therapy for regeneration of myocardial tissue, as well as neuromodulation of cardiac function. Dr. Penn has organized and lectured at international symposia and conferences, and is author or co-author of hundreds of articles, abstracts, book chapters and books on a wide range of topics in basic and translation science, and clinical medicine.
Dr. Penn is an active inventor, serial entrepreneur and internationally recognized as an expert in translating basic science research to clinical populations. He has generated intellectual property in the fields of diagnostics, biologics and devices that has been licensed by numerous companies, having authored dozens of U.S. and international patent applications. He is the founder of Juventas Therapeutics, Inc. (Cleveland, OH), a regenerative medicine company founded on his intellectual property based on novel fundamental concepts of endogenous stem cell mediated tissue repair pioneered by his group. As CMO of Juventas Therapeutics, Inc. (2007-2016) he designed and executed the Phase II studies STOP-CLI, STOP-HF, RETRO-HF and designed the STOP-PAD. His SDF-1 technology was optioned by Astellas Pharmaceutical in December of 2018. He was co-founder and CMO of Cleveland Heart Lab, Inc. (Cleveland, OH), a revenue stage diagnostic company based on biomarkers associated with coronary artery disease, myocardial infarction and other inflammatory diseases. Quest Diagnostics acquired Cleveland Heart Lab in December of 2017. He is a Senior Advisor to Quest Diagnostics and serves as the Medical Director for the Cardiovascular Metabolic and Endocrinology franchise.
From 2016-2019 as CEO of Black Beret Life Sciences, LLC (Houston, TX) where he oversaw the life science investments and led the executive teams of numerous companies including Tissue Genesis, LLC, (Honolulu, HI), Advanced Regen Medical Technologies, LLC, (Newark NJ), and the regenerative medicine treatment center, Okyanos (Freeport Bahamas), as well as the sugar replacement Sola (Houston, TX).
He is an advisor and board member of numerous companies. He is the PI of the Athersys MultiStem in AMI Phase I and II trials (Cleveland, OH), serves on the SMAB of NeuroTronik, Inc. (Raleigh, NC). He was a Venture Partner with Oakwood Medical Investors (2004-2010, St. Louis, MO), a member of the Advisory Board of Frantz Medical Ventures (2004-08, New York, NY), and a Clinical Partner with Foundation Medical Partners (2009-11, New Canaan, CT) where he represented the interests of the Cleveland Clinic. He was chair of the BOD of Cour Pharma (2007-2010, Kalamazoo, MI), and served on the BOD of CardioVIP (2012-2014, Houston, TX) and Non-Invasix (2016-2019 Houston, TX). He serves on the BOD of Rhythm Therapeutics (Chicago, IL), Keystone Bio (St. Louis, MO) and Diasome (Cleveland, OH). From 2008-10 Dr. Penn was the Senior Medical Director for Emerging Businesses at Cleveland Clinic. He was the 2006 Innovator of the Year, and in 2011 recognnized as one of the top 50 doctors in the history of the Cleveland Clinic (MedCity News).
Meet the Experts
Assistant Professor of Laboratory Medicine at Yale University
Joe El-Khoury, Ph.D., DABCC, FAACC is Assistant Professor of Laboratory Medicine at Yale University and Co-Director of the Clinical Chemistry Laboratory and Clinical Chemistry Fellowship program at Yale-New Haven Health.
Chair of the Division of Molecular Diagnostics, in the Department of Pathology at the Virginia Commonwealth University Health System
Andrea Ferreira-Gonzalez, Ph.D. is Chair of the Division of Molecular Diagnostics, in the Department of Pathology at the Virginia Commonwealth University Health System in July 2008. She is also the director of the Molecular Diagnostics Laboratory at the VCU Health System.
Associate Professor of Pathology and Laboratory Medicine at the University of Ottawa
Dr. Christopher McCudden, Ph.D., DABCC, FAACC, FCACB, Dr. McCudden is a Clinical Chemist at the Ottawa Hospital and an Associate Professor of Pathology and Laboratory Medicine in the Faculty of Medicine at the University of Ottawa.